Urinary Epidermal Growth Factor: A Promising "Next Generation" Biomarker in Kidney Disease.

Charlotte Cortvrindt, Reinhart Speeckaert, Joris R Delanghe, Marijn M Speeckaert

American journal of nephrology 2022

filter terms:

The epidermal growth factor (EGF) is a globular protein that is generated in the kidney, especially in the loop of Henle and the distal convoluted tubule. While EGF is nonexistent or hardly detectable in plasma, it is present in normal people's urine. Until now, risk stratification and chronic kidney disease (CKD) diagnosis have relied on estimated glomerular filtration rate (eGFR) and urine albumin/creatinine ratio (uACR), both of which reflect glomerular function or impairment. Tubular dysfunction, on the other hand, may also be associated with renal failure. Because decreased urine EGF (uEGF) indicates tubular atrophy and interstitial fibrosis, this biomarker, together with eGFR and uACR, may be employed in the general population for risk assessment and diagnosis of CKD. uEGF levels have been shown to correlate with intrarenal EGF mRNA expression and have been found to decrease in a variety of glomerular and non-glomerular kidney disorders. uEGF, uEGF/creatinine, or uEGF/monocyte chemotactic peptide-1 are possible "new generation" biomarkers linked to a variety of kidney diseases that deserve further investigation as a single biomarker or as part of a multi-biomarker panel. © 2022 S. Karger AG, Basel.

Citation

Charlotte Cortvrindt, Reinhart Speeckaert, Joris R Delanghe, Marijn M Speeckaert. Urinary Epidermal Growth Factor: A Promising "Next Generation" Biomarker in Kidney Disease. American journal of nephrology. 2022;53(5):372-387